Risk factors for COVID-19 associated pulmonary aspergillosis and outcomes in patients with acute respiratory failure in a respiratory sub-intensive care unit.
CAPA
COVID-19
Lymphocytopenia
Respiratory failure
Sub-intensive care unit
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
11 Apr 2024
11 Apr 2024
Historique:
received:
14
01
2024
accepted:
03
04
2024
medline:
12
4
2024
pubmed:
12
4
2024
entrez:
11
4
2024
Statut:
epublish
Résumé
COVID-19-associated pulmonary aspergillosis (CAPA) is burdened by high mortality. Data are lacking about non-ICU patients. Aims of this study were to: (i) assess the incidence and prevalence of CAPA in a respiratory sub-intensive care unit, (ii) evaluate its risk factors and (iii) impact on in-hospital mortality. Secondary aims were to: (i) assess factors associated to mortality, and (ii) evaluate significant features in hematological patients. This was a single-center, retrospective study of COVID-19 patients with acute respiratory failure. A cohort of CAPA patients was compared to a non-CAPA cohort. Among patients with CAPA, a cohort of hematological patients was further compared to another of non-hematological patients. Three hundred fifty patients were included in the study. Median P/F ratio at the admission to sub-intensive unit was 225 mmHg (IQR 155-314). 55 (15.7%) developed CAPA (incidence of 5.5%). Eighteen had probable CAPA (37.3%), 37 (67.3%) possible CAPA and none proven CAPA. Diagnosis of CAPA occurred at a median of 17 days (IQR 12-31) from SARS-CoV-2 infection. Independent risk factors for CAPA were hematological malignancy [OR 1.74 (95%CI 0.75-4.37), p = 0.0003], lymphocytopenia [OR 2.29 (95%CI 1.12-4.86), p = 0.02], and COPD [OR 2.74 (95%CI 1.19-5.08), p = 0.014]. Mortality rate was higher in CAPA cohort (61.8% vs 22.7%, p < 0.0001). CAPA resulted an independent risk factor for in-hospital mortality [OR 2.92 (95%CI 1.47-5.89), p = 0.0024]. Among CAPA patients, age > 65 years resulted a predictor of mortality [OR 5.09 (95% CI 1.20-26.92), p = 0.035]. No differences were observed in hematological cohort. CAPA is a life-threatening condition with high mortality rates. It should be promptly suspected, especially in case of hematological malignancy, COPD and lymphocytopenia.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19-associated pulmonary aspergillosis (CAPA) is burdened by high mortality. Data are lacking about non-ICU patients. Aims of this study were to: (i) assess the incidence and prevalence of CAPA in a respiratory sub-intensive care unit, (ii) evaluate its risk factors and (iii) impact on in-hospital mortality. Secondary aims were to: (i) assess factors associated to mortality, and (ii) evaluate significant features in hematological patients.
MATERIALS AND METHODS
METHODS
This was a single-center, retrospective study of COVID-19 patients with acute respiratory failure. A cohort of CAPA patients was compared to a non-CAPA cohort. Among patients with CAPA, a cohort of hematological patients was further compared to another of non-hematological patients.
RESULTS
RESULTS
Three hundred fifty patients were included in the study. Median P/F ratio at the admission to sub-intensive unit was 225 mmHg (IQR 155-314). 55 (15.7%) developed CAPA (incidence of 5.5%). Eighteen had probable CAPA (37.3%), 37 (67.3%) possible CAPA and none proven CAPA. Diagnosis of CAPA occurred at a median of 17 days (IQR 12-31) from SARS-CoV-2 infection. Independent risk factors for CAPA were hematological malignancy [OR 1.74 (95%CI 0.75-4.37), p = 0.0003], lymphocytopenia [OR 2.29 (95%CI 1.12-4.86), p = 0.02], and COPD [OR 2.74 (95%CI 1.19-5.08), p = 0.014]. Mortality rate was higher in CAPA cohort (61.8% vs 22.7%, p < 0.0001). CAPA resulted an independent risk factor for in-hospital mortality [OR 2.92 (95%CI 1.47-5.89), p = 0.0024]. Among CAPA patients, age > 65 years resulted a predictor of mortality [OR 5.09 (95% CI 1.20-26.92), p = 0.035]. No differences were observed in hematological cohort.
CONCLUSION
CONCLUSIONS
CAPA is a life-threatening condition with high mortality rates. It should be promptly suspected, especially in case of hematological malignancy, COPD and lymphocytopenia.
Identifiants
pubmed: 38605300
doi: 10.1186/s12879-024-09283-3
pii: 10.1186/s12879-024-09283-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
392Informations de copyright
© 2024. The Author(s).
Références
Lat A, Bhadelia N, Miko B, et al. Invasive aspergillosis after pandemic (H1N1) 2009. Emerg Infect Dis. 2010;16(6):971–3. https://doi.org/10.3201/eid1606.100165 .
doi: 10.3201/eid1606.100165
pubmed: 20507748
pmcid: 3086249
Shah MM, Hsiao EI, Kirsch CM, et al. Invasive pulmonary aspergillosis and influenza co-infection in immunocompetent hosts: case reports and review of the literature. Diagn Microbiol Infect Dis. 2018;91(2):147–52. https://doi.org/10.1016/j.diagmicrobio.2018.01.014 .
doi: 10.1016/j.diagmicrobio.2018.01.014
pubmed: 29454654
pmcid: 5970059
Milne-Price S, Miazgowicz KL, Munster VJ. The emergence of the Middle East respiratory syndrome coronavirus. Pathog Dis. 2014;71(2):121–36. https://doi.org/10.1111/2049-632X.12166 .
doi: 10.1111/2049-632X.12166
pubmed: 24585737
Verweij PE, Brüggemann RJM, Azoulay E, et al. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med. 2021;47(8):819–34. https://doi.org/10.1007/s00134-021-06449-4 .
doi: 10.1007/s00134-021-06449-4
pubmed: 34160631
pmcid: 8220883
Koehler P, Bassetti M, Chakrabarti A, European Confederation of Medical Mycology, International Society for Human Animal Mycology, Asia Fungal Working Group, INFOCUS LATAM/ISHAM Working Group, ISHAM Pan Africa Mycology Working Group, European Society for Clinical Microbiology, Infectious Diseases Fungal Infection Study Group, ESCMID Study Group for Infections in Critically Ill Patients, Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy, Medical Mycology Society of Nigeria, Medical Mycology Society of China Medicine Education Association, Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology, Association of Medical Microbiology, Infectious Disease Canada, et al. Lancet Infect Dis. 2021;21(6):149–62. https://doi.org/10.1016/S1473-3099(20)30847-1 .
doi: 10.1016/S1473-3099(20)30847-1
Mitaka H, Kuno T, Takagi H, et al. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis. Mycoses. 2021;64(9):993–1001. https://doi.org/10.1111/myc.13292 .
doi: 10.1111/myc.13292
pubmed: 33896063
pmcid: 8251156
Prattes J, Wauters J, Giacobbe DR, et al. ECMM-CAPA Study Group. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect. 2022;28(4):580–7. https://doi.org/10.1016/j.cmi.2021.08.014 .
doi: 10.1016/j.cmi.2021.08.014
pubmed: 34454093
Salmanton-García J, Sprute R, Stemler J, et al. FungiScope European Confederation of Medical Mycology/The International Society for Human and Animal Mycology Working Group. COVID-19-Associated Pulmonary Aspergillosis, March-August 2020. Emerg Infect Dis. 2021;27(4):1077–86. https://doi.org/10.3201/eid2704.204895 .
doi: 10.3201/eid2704.204895
pubmed: 33539721
pmcid: 8007287
Iqbal A, Ramzan M, Akhtar A, et al. COVID-Associated Pulmonary Aspergillosis and Its Related Outcomes: A Single-Center Prospective Observational Study. Cureus. 2021;13(8):e16982. https://doi.org/10.7759/cureus.16982 .
doi: 10.7759/cureus.16982
pubmed: 34527462
pmcid: 8421057
Lahmer T, Kriescher S, Herner A, et al. Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: Results from the prospective AspCOVID-19 study. PLoS ONE. 2021;16(3):e0238825. https://doi.org/10.1371/journal.pone.0238825 .
doi: 10.1371/journal.pone.0238825
pubmed: 33730058
pmcid: 7968651
Beltrame A, Stevens DA, Haiduven D. Mortality in ICU Patients with COVID-19-Associated Pulmonary Aspergillosis. J Fungi (Basel). 2023;9(6):689. https://doi.org/10.3390/jof9060689 .
doi: 10.3390/jof9060689
pubmed: 37367625
pmcid: 10305703
Calderón-Parra J, Mills-Sanchez P, Moreno-Torres V, HUPH IFI Study Group, et al. COVID-19-associated pulmonary aspergillosis (CAPA): Risk factors and development of a predictive score for critically ill COVID-19 patients. Mycoses. 2022;65(5):541–50. https://doi.org/10.1111/myc.13434 .
doi: 10.1111/myc.13434
pubmed: 35212030
pmcid: 9115267
Xu J, Yang X, Lv Z, et al. Risk Factors for Invasive Aspergillosis in Patients Admitted to the Intensive Care Unit With Coronavirus Disease 2019: A Multicenter Retrospective Study. Front Med (Lausanne). 2021;16(8):753659. https://doi.org/10.3389/fmed.2021.753659 .
doi: 10.3389/fmed.2021.753659
Bartoletti M, Pascale R, Cricca M, PREDICO Study Group, et al. Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. Clin Infect Dis. 2021;73(11):e3606–14. https://doi.org/10.1093/cid/ciaa1065 .
doi: 10.1093/cid/ciaa1065
pubmed: 32719848
Hurt W, Youngs J, Ball J et al. COVID-19-associated pulmonary aspergillosis in mechanically ventilated patients: a prospective, multicentre UK study. Thorax. 2023 Sep 1:thorax-2023–220002. https://doi.org/10.1136/thorax-2023-220002 .
Chong WH, Saha BK, Neu KP. Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis. Infection. 2022;50(1):43–56. https://doi.org/10.1007/s15010-021-01701-x .
doi: 10.1007/s15010-021-01701-x
pubmed: 34570355
Hong W, White PL, Backx M, et al. CT findings of COVID-19-associated pulmonary aspergillosis: a systematic review and individual patient data analysis. Clin Imaging. 2022;90:11–8. https://doi.org/10.1016/j.clinimag.2022.07.003 .
doi: 10.1016/j.clinimag.2022.07.003
pubmed: 35908455
pmcid: 9425042
Fischer T, El Baz Y, Graf N, et al. Clinical and Imaging Features of COVID-19-Associated Pulmonary Aspergillosis. Diagnostics (Basel). 2022;12(5):1201. https://doi.org/10.3390/diagnostics12051201 .
doi: 10.3390/diagnostics12051201
pubmed: 35626356
Hashim Z, Neyaz Z, Marak RSK, et al. Practice Guidelines for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis in an Intensive Care Setting. J Intensive Care Med. 2022;37(8):985–97. https://doi.org/10.1177/08850666211047166 .
doi: 10.1177/08850666211047166
pubmed: 34678103
pmcid: 9353310
White PL, Dhillon R, Cordey A, et al. A National Strategy to Diagnose Coronavirus Disease 2019-Associated Invasive Fungal Disease in the Intensive Care Unit. Clin Infect Dis. 2021;73(7):e1634–44. https://doi.org/10.1093/cid/ciaa1298 .
doi: 10.1093/cid/ciaa1298
pubmed: 32860682
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–33. https://doi.org/10.1001/jama.2012.5669 .
doi: 10.1001/jama.2012.5669
WHO. Clinical management of COVID-19. World Health Organization. Interim guidance 27 May, 2020. https://www.who.int/publications-detail/clinical-management-of-covid-19 . Date last updated: 23 Nov 2021. Date last accessed: 2 Jan 2024.
WHO. Clinical care of severe acute respiratory infections. https://www.who.int/publications/i/item/clinical-care-of-severe-acute-respiratory-infections-tool-kit . Date last updated: 6 Apr 2022. Date last accessed: 2 Jan 2024.
Oliva A, CogliatiDezza F, Petrucci F, et al. Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2 0 study. Clin Exp Med. 2023;23(6):2275–85. https://doi.org/10.1007/s10238-023-01027-y .
doi: 10.1007/s10238-023-01027-y
pubmed: 36867292
pmcid: 9982764
Oliva A, Ceccarelli G, Borrazzo C, et al. Comparison of clinical features and outcomes in COVID-19 and influenza pneumonia patients requiring intensive care unit admission. Infection. 2021;49(5):965–75. https://doi.org/10.1007/s15010-021-01624-7 .
doi: 10.1007/s15010-021-01624-7
pubmed: 34036458
pmcid: 8149291
Recovery Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693–704. https://doi.org/10.1056/NEJMoa2021436 .
doi: 10.1056/NEJMoa2021436
Hashim Z, Nath A, Khan A, et al. New insights into development and mortality of COVID-19-associated pulmonary aspergillosis in a homogenous cohort of 1161 intensive care patients. Mycoses. 2022;65(11):1010–23. https://doi.org/10.1111/myc.13485 .
doi: 10.1111/myc.13485
pubmed: 35716344
Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–60. https://doi.org/10.1182/blood-2002-05-1496 .
doi: 10.1182/blood-2002-05-1496
pubmed: 27365388
pmcid: 4967602
Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007;30(4):782–800. https://doi.org/10.1183/09031936.00062206 .
doi: 10.1183/09031936.00062206
pubmed: 17906086
Salazar F, Bignell E, Brown GD, et al. Pathogenesis of Respiratory Viral and Fungal Coinfections. Clin Microbiol Rev. 2022;35(1): e0009421. https://doi.org/10.1128/CMR.00094-21 .
doi: 10.1128/CMR.00094-21
pubmed: 34788127
Apostolopoulou A, Clancy CJ, Skeel A, et al. Invasive Pulmonary Aspergillosis Complicating Noninfluenza Respiratory Viral Infections in Solid Organ Transplant Recipients. Open Forum Infect Dis. 2021;8(11):ofab478. https://doi.org/10.1093/ofid/ofab478 .
doi: 10.1093/ofid/ofab478
pubmed: 34805426
pmcid: 8600160
Dimopoulos G, Almyroudi MP, Myrianthefs P, et al. COVID-19-Associated Pulmonary Aspergillosis (CAPA). J Intensive Med. 2021;1(2):71–80. https://doi.org/10.1016/j.jointm.2021.07.001 .
doi: 10.1016/j.jointm.2021.07.001
pubmed: 36785564
pmcid: 8346330
Tavakoli M, Shokohi T, Lass Flörl C, et al. Immunological response to COVID-19 and its role as a predisposing factor in invasive aspergillosis. Curr Med Mycol. 2020;6(4):75–9. https://doi.org/10.18502/cmm.6.4.5442 .
doi: 10.18502/cmm.6.4.5442
pubmed: 34195465
pmcid: 8226042
Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9. https://doi.org/10.1172/JCI137244 .
doi: 10.1172/JCI137244
pubmed: 32217835
pmcid: 7190990
Crum-Cianflone NF. Invasive Aspergillosis Associated With Severe Influenza Infections. Open Forum Infect Dis. 2016;3(3):ofw171. https://doi.org/10.1093/ofid/ofw171 .
doi: 10.1093/ofid/ofw171
pubmed: 27704024
pmcid: 5047415